Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.
|NCPE Assessment Process||Complete|
|Rapid review received||10/09/2018|
|Rapid review completed||18/10/2018|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of axi-cel compared with the current standard of care.
|Full pharmacoeconomic assessment commissioned by HSE||22/10/2018|
|Pre-submission consultation with Applicant||03/12/2018|
|Submission received from applicant||20/03/2019|
|Current Status||HTA submission received|